Use of androgen deprivation therapy (ADT) may be associated with an increased risk of Alzheimer’s disease, according to a recent study published online ahead of print in the Journal of Clinical Oncology.1
Kevin Nead, MD, MPhil , of the Hospital of the University of Pennsylvania in Philadelphia, and colleagues conducted a retrospective cohort study of 16 888 men with prostate cancer in a previously validated and implemented text-processing pipeline.
They tested the effect of ADT on risk of Alzheimer’s using 1 to 5 propensity score-matched and traditional multivariable-adjusted Cox proportional hazards models.
Among 2397 men who received ADT with a median follow-up of 2.7 years, both hazards models suggested a statistically significant association between ADT use and Alzheimer’s disease risk.
RELATED: Initial Gleason Score Does Not Impact Abiraterone Benefit in Prostate Cancer
They also observed a statistically significant increase in risk of Alzheimer’s with higher duration of ADT.
“This study demonstrates the utility of novel methods to analyze electronic medical record data to generate practice-based evidence,” the authors concluded.
- Nead KT, Gaskin G, Chester C, et al. Androgen deprivation therapy and future Alzheimer’s disease risk [published online ahead of print December 7, 2015]. J Clin. Oncol. doi: 10.1200/JCO.2015.63.6266.